Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies DOI Creative Commons
Shahab Mehdizadeh,

Mobin Mamaghani,

Somayyeh Hassanikia

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: May 3, 2025

The blood-brain barrier (BBB) presents a formidable challenge in neuropharmacology, limiting the delivery of therapeutic agents to brain. Exosomes, nature's nanocarriers, have emerged as promising solution due their biocompatibility, low immunogenicity, and innate ability traverse BBB. A thorough examination BBB anatomy physiology reveals complexities neurological drug underscores limitations conventional methods. This review explores potential exosome-powered neuropharmaceutics, highlighting structural functional properties, biogenesis, mechanisms release. Their intrinsic advantages delivery, including enhanced stability efficient cellular uptake, are discussed detail. Exosomes naturally overcome barriers through specific translocation mechanisms, making them compelling vehicle for targeted brain therapies. Advances engineering strategies, such genetic biochemical modifications, loading techniques, specificity enhancement, further bolster potential. Exosome-based approaches hold immense promise treating spectrum disorders, Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), multiple (MS), tumors, stroke, psychiatric conditions. By leveraging properties innovations, exosomes offer versatile platform precision neurotherapeutics. Despite promise, challenges remain clinical translation, large-scale production, standardization, regulatory considerations. Future research directions exosome nanobiotechnology aim refine these unlocking new avenues diseases. transformative impact exosome-based paving way next-generation therapies that can effectively penetrate revolutionize neuropharmacology.

Language: Английский

Extracellular vesicles for developing targeted hearing loss therapy DOI

Xiaoshu Pan,

Yanjun Li, Peixin Huang

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 366, P. 460 - 478

Published: Jan. 11, 2024

Language: Английский

Citations

3

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity DOI

En‐Li Yang,

Zhi‐Jun Sun

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(9)

Published: Jan. 30, 2024

Abstract Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents tumor microenvironment (TME), exacerbates this issue by fostering immunosuppression and impeding T cell differentiation maturation. Consequently, targeting MDSCs has emerged as for immunotherapy aimed at enhancing anti‐tumor responses. development nanomedicines specifically designed target improve effectiveness transforming immunosuppressive tumors into ones more responsive intervention. This review provides detailed overview in TME current strategies these cells. Also benefits nanoparticle‐assisted drug delivery systems, including design flexibility, efficient loading, protection against enzymatic degradation, are highlighted. It summarizes advances nanomedicine MDSCs, covering enhanced treatment efficacy, safety, modulation TME, laying groundwork potent cancer immunotherapy.

Language: Английский

Citations

3

Functional Evaluation of Niosomes Utilizing Surfactants in Nanomedicine Applications DOI Creative Commons

Shuqi Gao,

Zhe Sui, Qian Jiang

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 10283 - 10305

Published: Oct. 1, 2024

Abstract: Niosomes are key nanocarriers composed of bilayer vesicles formed by non-ionic surfactants and cholesterol, offering advantages such as high physicochemical stability, biodegradability, cost-effectiveness, low toxicity. This review discusses their significant role in drug delivery, including applications anticancer therapy vaccine delivery. It also highlights the impact on niosome formation, delivery pathways, protein corona formation—a relatively underexplored topic. Furthermore, application artificial intelligence optimizing design functionality is examined. Future research directions include enhancing formulation techniques, expanding scopes, integrating advanced technologies. provides comprehensive insights practical guidance for advancing niosome-based systems. Keywords: niosomes, surfactant, systems, functionalization

Language: Английский

Citations

3

Extracellular Vesicles: Advanced Tools for Disease Diagnosis, Monitoring, and Therapies DOI Open Access
Pedro Lorite, Jorge N. Domínguez, Teresa Palomeque

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 26(1), P. 189 - 189

Published: Dec. 29, 2024

Extracellular vesicles (EVs) are a heterogeneous group of membrane-encapsulated released by cells into the extracellular space. They play crucial role in intercellular communication transporting bioactive molecules such as proteins, lipids, and nucleic acids. EVs can be detected body fluids, including blood plasma, urine, saliva, amniotic fluid, breast milk, pleural ascites. The complexity diversity require robust standardized approach. By adhering to protocols guidelines, researchers ensure consistency, purity, reproducibility isolated EVs, facilitating their use diagnostics, therapies, research. Exosomes microvesicles represent an exciting frontier modern medicine, with significant potential transform diagnosis treatment various diseases important personalized medicine precision therapy. primary objective this review is provide updated analysis significance highlighting mechanisms action exploring applications diseases. Additionally, addresses existing limitations future offering practical recommendations resolve current challenges enhance viability for clinical use. This comprehensive approach aims bridge gap between EV research its application healthcare.

Language: Английский

Citations

3

Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies DOI Creative Commons
Shahab Mehdizadeh,

Mobin Mamaghani,

Somayyeh Hassanikia

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: May 3, 2025

The blood-brain barrier (BBB) presents a formidable challenge in neuropharmacology, limiting the delivery of therapeutic agents to brain. Exosomes, nature's nanocarriers, have emerged as promising solution due their biocompatibility, low immunogenicity, and innate ability traverse BBB. A thorough examination BBB anatomy physiology reveals complexities neurological drug underscores limitations conventional methods. This review explores potential exosome-powered neuropharmaceutics, highlighting structural functional properties, biogenesis, mechanisms release. Their intrinsic advantages delivery, including enhanced stability efficient cellular uptake, are discussed detail. Exosomes naturally overcome barriers through specific translocation mechanisms, making them compelling vehicle for targeted brain therapies. Advances engineering strategies, such genetic biochemical modifications, loading techniques, specificity enhancement, further bolster potential. Exosome-based approaches hold immense promise treating spectrum disorders, Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), multiple (MS), tumors, stroke, psychiatric conditions. By leveraging properties innovations, exosomes offer versatile platform precision neurotherapeutics. Despite promise, challenges remain clinical translation, large-scale production, standardization, regulatory considerations. Future research directions exosome nanobiotechnology aim refine these unlocking new avenues diseases. transformative impact exosome-based paving way next-generation therapies that can effectively penetrate revolutionize neuropharmacology.

Language: Английский

Citations

0